<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJS</journal-id>
<journal-id journal-id-type="hwp">spijs</journal-id>
<journal-id journal-id-type="nlm-ta">Int J Surg Pathol</journal-id>
<journal-title>International Journal of Surgical Pathology</journal-title>
<issn pub-type="ppub">1066-8969</issn>
<issn pub-type="epub">1940-2465</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1066896912457201</article-id>
<article-id pub-id-type="publisher-id">10.1177_1066896912457201</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Minute Type I Gastric Carcinoid With Regional Lymph Node Metastasis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Lupinacci</surname><given-names>Renato Micelli</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912457201">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dias</surname><given-names>André Roncon</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-1066896912457201">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mello</surname><given-names>Evandro Sobroza</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-1066896912457201">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kondo</surname><given-names>André</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912457201">1</xref>
<xref ref-type="aff" rid="aff2-1066896912457201">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1066896912457201"><label>1</label>Hospital do Servidor Estadual, Sao Paulo, Brazil</aff>
<aff id="aff2-1066896912457201"><label>2</label>Sao Paulo State Cancer Institute, Sao Paulo, Brazil</aff>
<author-notes>
<corresp id="corresp1-1066896912457201">André Kondo, Department of Surgery, Hospital do Servidor Estadual, Av. Angélica, 2503, conj 71, Higienópolis, Sao Paulo, SP, Brazil Email: <email>andrekondo@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>21</volume>
<issue>2</issue>
<fpage>169</fpage>
<lpage>172</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Type I gastric carcinoids are indolent lesions that only rarely metastasize. Until now, lymph node metastasis had only being observed in large (≥10 mm) and usually invasive lesions (deep submucosa or beyond). This study reports a diminutive (8 mm) gastric carcinoid, limited to the superficial layer of the submucosa (sm1), with no angiovascular invasion, but with a high Ki-67 index (7%) and an involved perigastric lymph node. The aggressive behavior of this lesion ends the previous believe that small and superficial type I gastric carcinoids do not metastasize. This case also indicates that better parameters are necessary to evaluate the malignant potential of these lesions and presents a further support to the value of 2010 World Health Organization classification of gastrointestinal neuroendocrine tumors.</p>
</abstract>
<kwd-group>
<kwd>gastric carcinoid type I</kwd>
<kwd>neuroendocrine tumor</kwd>
<kwd>lymph node metastasis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1066896912457201" sec-type="intro">
<title>Introduction</title>
<p>The incidence of gastric carcinoid (GC) tumors is increasing.<sup><xref ref-type="bibr" rid="bibr1-1066896912457201">1</xref></sup> The widespread use of upper gastrointestinal (GI) endoscopy and the better knowledge and awareness of these well-differentiated neuroendocrine tumors (NETs) are the main reasons for this fact.<sup><xref ref-type="bibr" rid="bibr2-1066896912457201">2</xref></sup></p>
<p>Gastric carcinoids derive from enterochromaffin-like (ECL) cells and can be classified in 3 subtypes (<xref ref-type="table" rid="table1-1066896912457201">Table 1</xref>).<sup><xref ref-type="bibr" rid="bibr3-1066896912457201">3</xref></sup> Mention must be made to 3 recent reports of what would be a new subtype of GC, associated with hypergastrinemia due to an intrinsic block in the acid secretion.<sup><xref ref-type="bibr" rid="bibr4-1066896912457201">4</xref></sup> Currently, the therapeutic strategy for GCs is based on this classification. Type I GCs are usually small, restricted to the mucosa and only rarely spread, carrying a good prognosis. Until now, only large lesions (≥10 mm) or carcinoids invading the deep submucosa or beyond were known to have a chance to metastasize to lymph nodes or liver. Here, we present the case of a 52-year-old patient who had a small and superficial type I GC and a regional metastasis.</p>
<table-wrap id="table1-1066896912457201" position="float">
<label>Table 1.</label>
<caption><p>Gastric Carcinoids Classification</p></caption>
<graphic alternate-form-of="table1-1066896912457201" xlink:href="10.1177_1066896912457201-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Type</th>
<th align="center">Characteristics</th>
<th align="center">Gastrinemia</th>
<th align="center">Frequency (%)</th>
<th align="center">Behavior</th>
<th align="center">Association</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Small (&lt;1 cm) and multiples</td>
<td>High</td>
<td>68-83</td>
<td>Rarely metastasize</td>
<td>Chronic atrophic gastritis type A</td>
</tr>
<tr>
<td>II</td>
<td>Small (&lt;1cm) and multiples</td>
<td>High</td>
<td>~7</td>
<td>Occasionally metastasize</td>
<td>Hypertrophic gastropathy related to multiple endocrine neoplasia type 1 (MEN-1), Zollinger–Ellison syndrome</td>
</tr>
<tr>
<td>III</td>
<td>Large (&gt;1cm) and solitary</td>
<td>Normal</td>
<td>~23</td>
<td>Moderately aggressive</td>
<td>No gastric pathology (sporadic cancer carcinoids)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section2-1066896912457201" sec-type="cases">
<title>Case Report</title>
<p>A 52-year-old man was referred to our hospital for further evaluation because of multiple small elevated lesions on the gastric body. He presented progressive asthenia in the past 30 days and his hematologic study revealed anemia (hemoglobin level of 7.4 g/dL) and hypergastrinemia (serum gastrin level of 891 pg/mL). Other laboratory data values were all within the normal limits, including, chromogranin A serum level and urinary 5-hydroxyindoleacetic acid in a 24-hour sample. Upper GI endoscopy revealed atrophic gastritis and multiple small (&lt;0.4 cm) gastric body lesions. Polipectomies were performed revealing type I carcinoid tumors, all restricted to the mucosa, with a low Ki-67 index (&lt;3%). During the follow-up, the patient sustained normal levels of seric chromogranin A and urinary 5-hydroxyindoleacetic acid. New endoscopies were performed at postresection months 3, 6, and 12 and additional type I carcinoid lesions (all superficial with low Ki-67) were observed in all exams. The patient was then indicated for surgery. Preoperative computed tomography scan of the abdomen was unremarkable and a total gastrectomy with perigastric (D1) lymphadenectomy plus the removal of lymph node station number 7 (left gastric artery) was performed.</p>
<p>Macroscopically, 6 elevated lesions (4-8 mm) were found. At the histologic level, an atrophic gastritis with endocrine cell hyperplasia was present and all lesions were confirmed as carcinoid tumors. Additionally, all except the largest one (8 mm), were restricted to the mucosa. The 8-mm lesion was located at the gastric fundus, being invasive to the superficial layer of the submucosa (sm1). Invasion was analysed in multiple sections. Angioinvasion was absent (confirmed with CD34 imunnohistochemistry) and metastasis occurred in 1 of 24 dissected lymph nodes (located at lymph node station number 3). One mitosis per 10 high-power fields (HPF) was observed, and Ki-67 labeling index was 7% (counted from 1000 cells in the “hot spot” area of the tumor), resulting in a final diagnosis of gastric NET grade 2 according to the classification proposed by the World Health Organization (WHO) in 2010.<sup><xref ref-type="bibr" rid="bibr5-1066896912457201">5</xref></sup> Histologic analysis and immunohistochemistry testing were performed twice, in 2 different centers, by 2 different GI pathologists, to confirm the unexpected findings.</p>
<p>Recovery was uneventful and the patient discharged home at postoperative day 8. He remains disease free after 14 months. Urinary 5-hydroxyindoleacetic acid levels and serum chromogranin A levels were at normal levels at postoperative months 3, 6, 9, and 12. Thoraco-abdominal computed tomography scan was also unremarkable at months 6 and 12.</p>
</sec>
<sec id="section3-1066896912457201" sec-type="discussion">
<title>Discussion</title>
<p>Almost all GCs are incidentally found during upper GI endoscopy and up to 83% of these tumors can be classified as type I lesions.<sup><xref ref-type="bibr" rid="bibr1-1066896912457201">1</xref>,<xref ref-type="bibr" rid="bibr6-1066896912457201">6</xref><xref ref-type="bibr" rid="bibr7-1066896912457201"/><xref ref-type="bibr" rid="bibr8-1066896912457201"/>-<xref ref-type="bibr" rid="bibr9-1066896912457201">9</xref></sup> Type I GCs are usually small, multiple, and associated with hypergastrinemia due to parietal cells loss and hyperstimulation of antral G-cell.<sup><xref ref-type="bibr" rid="bibr10-1066896912457201">10</xref></sup> ECL cells hyperplasia occurs and autoimmune-related pernicious anemia or type A chronic atrophic gastritis may be present.</p>
<p>In the past, type I GCs were treated by gastrectomy, but nowadays most of these lesions are managed by endoscopic resection, since they are usually benign and well differentiated, carrying excellent prognosis (5-year disease-related survival approaches 100%).<sup><xref ref-type="bibr" rid="bibr8-1066896912457201">8</xref>,<xref ref-type="bibr" rid="bibr11-1066896912457201">11</xref><xref ref-type="bibr" rid="bibr12-1066896912457201"/>-<xref ref-type="bibr" rid="bibr13-1066896912457201">13</xref></sup> The clinical management of these lesions with long-acting somatostatin analogues has also been reported with good results in small groups of patients.<sup><xref ref-type="bibr" rid="bibr14-1066896912457201">14</xref>,<xref ref-type="bibr" rid="bibr15-1066896912457201">15</xref></sup></p>
<p>As the most important predictor for survival is the presence of metastatic disease,<sup><xref ref-type="bibr" rid="bibr5-1066896912457201">5</xref>,<xref ref-type="bibr" rid="bibr8-1066896912457201">8</xref></sup> surgery is usually reserved for patients with large lesions (&gt;2 cm), tumors not suitable for endoscopic resection, recurrent disease, deep wall invasion (deep submucosa and beyond), signs of lymph node involvement, and when an adenocarcinoma is also present.<sup><xref ref-type="bibr" rid="bibr11-1066896912457201">11</xref>,<xref ref-type="bibr" rid="bibr16-1066896912457201">16</xref>,<xref ref-type="bibr" rid="bibr17-1066896912457201">17</xref></sup> Controversy exists concerning the best surgical procedure for type I GC. Some authors propose an antrectomy to remove the gastrin-producing G-cells.<sup><xref ref-type="bibr" rid="bibr8-1066896912457201">8</xref>,<xref ref-type="bibr" rid="bibr12-1066896912457201">12</xref>,<xref ref-type="bibr" rid="bibr18-1066896912457201">18</xref>,<xref ref-type="bibr" rid="bibr19-1066896912457201">19</xref></sup> Failure to reduce the hypergastrinemia because of inadequate removal of the antrum, distal stomach and duodenal cap may occur, as well as the chance for persistent or recurrent GC since ECL cells may become autonomous or gastrin independent.<sup><xref ref-type="bibr" rid="bibr11-1066896912457201">11</xref></sup> Alternatives consist in the partial or total removal of the stomach. The total gastrectomy performed in the present case was decided based on the presence of recurrent, multiple and diffuse carcinoids. The patient was also informed and consented with the choice.</p>
<p>As inferred from the surgical indications, superficial small type I carcinoids are not expected to have local or distant metastasis, which are usually associated with large lesions and/or deep wall invasion, as observed in <xref ref-type="table" rid="table2-1066896912457201">Table 2</xref>. From the known type I GCs with lymph node metastasis, there are 2 reports of superficial lesions with liver metastasis with no size information: One consisted of a type I GC invading the muscularis mucosa with lymph node and liver metastasis in a patient with mutiple carcinoids whose largest one was initially mistaken for an adenocarcinoma in the upper GI endoscopy,<sup><xref ref-type="bibr" rid="bibr20-1066896912457201">20</xref></sup> and the other consisted of a submucosal carcinoid with liver metastasis and, although the authors did not specify the size of the lesion, the median tumor diameter in their article was 10 mm and they state that a positive correlation between tumor diameter and invasiveness, as well as the presence of metastasis, was observed.<sup><xref ref-type="bibr" rid="bibr8-1066896912457201">8</xref></sup> A large series<sup><xref ref-type="bibr" rid="bibr9-1066896912457201">9</xref></sup> also observed that size and, more important, the degree of wall invasion were significantly associated with metastatic disease. Only 3 of 94 (3%) GCs that were ≤1 cm were metastatic. Additionally, the degree of invasion in the submucosa greatly correlated with the metastatic potential: None of 32 intramucosal and of 48 muscularis mucosae/superficial submucosa carcinoids had metastasis at diagnosis or during follow-up, while a significant malignant potential for GCs invading the deep submucosa was observed, with 11 out of 38 patients (29%) presenting metastasis at the time of the diagnosis (24%) or during follow-up (5%). This could explain why Soga<sup><xref ref-type="bibr" rid="bibr6-1066896912457201">6</xref></sup> observed a high metastatic rate for small GCs (≤1 cm) invading the submucosa (9.6%); unfortunately, the level of invasion was not detailed in the article.</p>
<table-wrap id="table2-1066896912457201" position="float">
<label>Table 2.</label>
<caption><p>All Known Type I Gastric Carcinoids With Local or Distant Metastasis</p></caption>
<graphic alternate-form-of="table2-1066896912457201" xlink:href="10.1177_1066896912457201-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Reference</th>
<th align="center">Wall Invasion</th>
<th align="center">Additional Information</th>
<th align="center">Tumor Size (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Borch et al<sup><xref ref-type="bibr" rid="bibr8-1066896912457201">8</xref></sup></td>
<td>Submucosa</td>
<td>1 liver metastasis</td>
<td>≥10<sup><xref ref-type="table-fn" rid="table-fn1-1066896912457201">a</xref></sup></td>
</tr>
<tr>
<td/>
<td>Subserosa</td>
<td>1 perigastric lymph node</td>
<td>10-40</td>
</tr>
<tr>
<td/>
<td>Serosa</td>
<td>1 regional lymph node</td>
<td>50-80</td>
</tr>
<tr>
<td/>
<td>Serosa</td>
<td>1 regional lymph node</td>
<td>50-80</td>
</tr>
<tr>
<td>Solcia et al<sup><xref ref-type="bibr" rid="bibr17-1066896912457201">17</xref></sup></td>
<td>Muscular or beyond</td>
<td>Local lymph node</td>
<td>Not reported</td>
</tr>
<tr>
<td/>
<td>Muscular or beyond</td>
<td>Local lymph node</td>
<td>Not reported</td>
</tr>
<tr>
<td/>
<td>Muscular or beyond</td>
<td>Local lymph node</td>
<td>Not reported</td>
</tr>
<tr>
<td>Gladdy et al<sup><xref ref-type="bibr" rid="bibr11-1066896912457201">11</xref></sup></td>
<td>Not reported</td>
<td>Local lymph node</td>
<td>19</td>
</tr>
<tr>
<td/>
<td>Not reported</td>
<td>Lymph node + gastric adenocarcinoma</td>
<td>27 ± 9</td>
</tr>
<tr>
<td/>
<td>Not reported</td>
<td>Lymph node + gastric adenocarcinoma</td>
<td>27 ± 9</td>
</tr>
<tr>
<td>Jordan et al<sup><xref ref-type="bibr" rid="bibr12-1066896912457201">12</xref><xref ref-type="table-fn" rid="table-fn2-1066896912457201">b</xref></sup></td>
<td>Serosa</td>
<td>Local lymph node</td>
<td>15</td>
</tr>
<tr>
<td/>
<td>Serosa</td>
<td>Local lymph node</td>
<td>Not reported</td>
</tr>
<tr>
<td/>
<td>Serosa</td>
<td>Local lymph node</td>
<td>Not reported</td>
</tr>
<tr>
<td>La Rosa et al<sup><xref ref-type="bibr" rid="bibr9-1066896912457201">9</xref><xref ref-type="table-fn" rid="table-fn2-1066896912457201">b</xref></sup></td>
<td>Deep submucosa<sup><xref ref-type="table-fn" rid="table-fn3-1066896912457201">c</xref></sup></td>
<td>Local or distant metastasis</td>
<td>≤10</td>
</tr>
<tr>
<td/>
<td>Deep submucosa<sup><xref ref-type="table-fn" rid="table-fn3-1066896912457201">c</xref></sup></td>
<td>Local or distant metastasis</td>
<td>≤10</td>
</tr>
<tr>
<td>Granberg et al<sup><xref ref-type="bibr" rid="bibr20-1066896912457201">20</xref></sup></td>
<td>Muscularis mucosae</td>
<td>Lymph node and liver metastasis</td>
<td>Not reported<sup><xref ref-type="table-fn" rid="table-fn4-1066896912457201">d</xref></sup></td>
</tr>
<tr>
<td>Present case</td>
<td>Submucosa</td>
<td>1 perigastric lymph node</td>
<td>8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1066896912457201">
<label>a</label>
<p>Lesion’s size is unclear</p>
</fn>
<fn id="table-fn2-1066896912457201">
<label>b</label>
<p>Unclear if all cases were type I gastric carcinoids.</p>
</fn>
<fn id="table-fn3-1066896912457201">
<label>c</label>
<p>Deep submucosa or beyond.</p>
</fn>
<fn id="table-fn4-1066896912457201">
<label>d</label>
<p>Lesion was mistaken for an adenocarcinoma</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Still concerning the metastatic potential, not only are the size and depth of wall invasion significant but also the degree of structural differentiation, cytologic atypia, necrosis, angioinvasion, and proliferative rates with mitotic count and Ki-67 index. Solcia et al<sup><xref ref-type="bibr" rid="bibr17-1066896912457201">17</xref></sup> noticed that a lesion size over 2 cm, a Ki-67 proliferative index of more than 3%, or with more than 150 positive cells for Ki-67 per 10 HPF, were indicative for malignant GCs. Additionally, they observed that a Ki-67 ≤130/10 HPF and the absence of angioinvasion perfectly predicted nonmalignancy in their cases. Other authors also reported angioinvasion as a powerful predictor for malignant behavior<sup><xref ref-type="bibr" rid="bibr9-1066896912457201">9</xref></sup>; however, the absence of angioinvasion should not be used to rule out malignancy, as observed in the present report.</p>
<p>The recently published European Neuroendocrine Tumor Society Consensus Guidelines state that all cases should undergo immunohistochemical staining, including chromogranin A and synaptophysin testing. Also, mitotic count in 10 HPF and the Ki-67 index are mandatory (although the techniques and counting standards need to be further established).<sup><xref ref-type="bibr" rid="bibr21-1066896912457201">21</xref></sup> Ki-67 is also useful to classify patients accordingly to the 2010 WHO classification of GI NETs. In the present case, Ki67 index was 7% and, therefore, the lesion was classified as grade 2. As up to 97% type I GCs are grade 1,<sup><xref ref-type="bibr" rid="bibr9-1066896912457201">9</xref></sup> with excellent prognosis, our findings support the prognostic value of the WHO classification, as the lesion had an unexpected lymph node metastasis, which might have been overlooked if the management continued with endoscopic resections and no attention was given to the high Ki-67 index in one of the lesions.</p>
<p>To our knowledge, the present report is the first one of a diminutive lesion (&lt;10 mm) restricted to the superficial submucosa and without angiovascular invasion to have nodal involvement. This highlights the need to better understand the behavior of GCs and to precisely classify them.<sup><xref ref-type="bibr" rid="bibr22-1066896912457201">22</xref></sup> After all, how do we identify those patients with small type I GCs that have bad prognosis and should undergo surgical management? Should we base our decision on the grade provided by the 2010 WHO classification alone? Should we indicate a gastrectomy with lymph node dissection for all lesions with a high Ki-67 index? These questions remain to be answered.</p>
<p>In summary, endoscopic resection and follow-up are still the best approach for type I GCs. However, this single case indicates that histologic and proliferative parameters must be considered to evaluate the aggressiveness of GCs, so that the therapeutic strategy can be tailored accordingly.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1066896912457201">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Modlin</surname><given-names>IM</given-names></name>
<name><surname>Oberg</surname><given-names>K</given-names></name>
<name><surname>Chung</surname><given-names>DC</given-names></name><etal/>
</person-group>. <article-title>Gastroenteropancreatic neuroendocrine tumors</article-title>. <source>Lancet Oncol</source>. <year>2008</year>;<volume>9</volume>:<fpage>61</fpage>-<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr2-1066896912457201">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hassan</surname><given-names>MM</given-names></name>
<name><surname>Phan</surname><given-names>A</given-names></name>
<name><surname>Li</surname><given-names>D</given-names></name>
<name><surname>Dagohoy</surname><given-names>CG</given-names></name>
<name><surname>Leary</surname><given-names>C</given-names></name>
<name><surname>Yao</surname><given-names>JC.</given-names></name>
</person-group> <article-title>Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study</article-title>. <source>Int J Cancer</source>. <year>2008</year>;<volume>123</volume>:<fpage>867</fpage>-<lpage>873</lpage>.</citation>
</ref>
<ref id="bibr3-1066896912457201">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rindi</surname><given-names>G</given-names></name>
<name><surname>Luinetti</surname><given-names>O</given-names></name>
<name><surname>Cornaggia</surname><given-names>M</given-names></name>
<name><surname>Capella</surname><given-names>C</given-names></name>
<name><surname>Solcia</surname><given-names>E.</given-names></name>
</person-group> <article-title>Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study</article-title>. <source>Gastroenterology</source>. <year>1993</year>;<volume>104</volume>:<fpage>994</fpage>-<lpage>1006</lpage>.</citation>
</ref>
<ref id="bibr4-1066896912457201">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nakata</surname><given-names>K</given-names></name>
<name><surname>Aishima</surname><given-names>S</given-names></name>
<name><surname>Ichimiya</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Unusual multiple gastric carcinoids with hypergastrinemia: report of a case</article-title>. <source>Surg Today</source>. <year>2010</year>;<volume>40</volume>:<fpage>267</fpage>-<lpage>271</lpage>.</citation>
</ref>
<ref id="bibr5-1066896912457201">
<label>5.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Rindi</surname><given-names>G</given-names></name>
<name><surname>Arnold</surname><given-names>R</given-names></name>
<name><surname>Bosman</surname><given-names>FT</given-names></name>
<etal/>
</person-group>. <article-title>Nomenclature and classification of neuroendocrine neoplasms of the digestive system</article-title>. In: <person-group person-group-type="editor">
<name><surname>Bosman</surname><given-names>FT</given-names></name>
<name><surname>Carneiro</surname><given-names>F</given-names></name>
<name><surname>Hruban</surname><given-names>RH</given-names></name>
<name><surname>Theise</surname><given-names>ND</given-names></name>
</person-group>, eds. <source>WHO Classification of Tumors of the Digestive System</source>. <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>IARC Press</publisher-name>; <volume>2010</volume>:<fpage>13</fpage>-<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr6-1066896912457201">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soga</surname><given-names>J.</given-names></name>
</person-group> <article-title>Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases</article-title>. <source>Cancer</source>. <year>2005</year>;<volume>103</volume>:<fpage>1587</fpage>-<lpage>1595</lpage>.</citation>
</ref>
<ref id="bibr7-1066896912457201">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Modlin</surname><given-names>IM</given-names></name>
<name><surname>Lye</surname><given-names>KD</given-names></name>
<name><surname>Kidd</surname><given-names>M.</given-names></name>
</person-group> <article-title>A 5-decade analysis of 13,715 carcinoid tumors</article-title>. <source>Cancer</source>. <year>2003</year>;<volume>97</volume>:<fpage>934</fpage>-<lpage>959</lpage>.</citation>
</ref>
<ref id="bibr8-1066896912457201">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Borch</surname><given-names>K</given-names></name>
<name><surname>Ahrén</surname><given-names>B</given-names></name>
<name><surname>Ahlman</surname><given-names>H</given-names></name>
<name><surname>Falkmer</surname><given-names>S</given-names></name>
<name><surname>Granérus</surname><given-names>G</given-names></name>
<name><surname>Grimelius</surname><given-names>L.</given-names></name>
</person-group> <article-title>Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type</article-title>. <source>Ann Surg</source>. <year>2005</year>;<volume>242</volume>:<fpage>64</fpage>-<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr9-1066896912457201">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>La Rosa</surname><given-names>S</given-names></name>
<name><surname>Inzani</surname><given-names>F</given-names></name>
<name><surname>Vanoli</surname><given-names>A</given-names></name>
<etal/>
</person-group>: <article-title>Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms</article-title>. <source>Hum Pathol</source>. <year>2011</year>;<volume>42</volume>:<fpage>1373</fpage>-<lpage>1384</lpage>.</citation>
</ref>
<ref id="bibr10-1066896912457201">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rindi</surname><given-names>G</given-names></name>
<name><surname>Bordi</surname><given-names>C</given-names></name>
<name><surname>Rappel</surname><given-names>S</given-names></name>
<name><surname>La Rosa</surname><given-names>S</given-names></name>
<name><surname>Stolte</surname><given-names>M</given-names></name>
<name><surname>Solcia</surname><given-names>E.</given-names></name>
</person-group> <article-title>Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior</article-title>. <source>World J Surg</source>. <year>1996</year>;<volume>20</volume>:<fpage>168</fpage>-<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr11-1066896912457201">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gladdy</surname><given-names>RA</given-names></name>
<name><surname>Strong</surname><given-names>VE</given-names></name>
<name><surname>Coit</surname><given-names>D</given-names></name><etal/>
</person-group>. <article-title>Defining surgical indications for type I gastric carcinoid tumor</article-title>. <source>Ann Surg Oncol</source>. <year>2009</year>;<volume>16</volume>:<fpage>3154</fpage>-<lpage>3160</lpage>.</citation>
</ref>
<ref id="bibr12-1066896912457201">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jordan</surname><given-names>PH</given-names><suffix>Jr</suffix></name>
<name><surname>Barroso</surname><given-names>A</given-names></name>
<name><surname>Sweeney</surname><given-names>J.</given-names></name>
</person-group> <article-title>Gastric carcinoids in patients with hypergastrinemia</article-title>. <source>J Am Coll Surg</source>. <year>2004</year>;<volume>199</volume>:<fpage>552</fpage>-<lpage>555</lpage>.</citation>
</ref>
<ref id="bibr13-1066896912457201">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schindl</surname><given-names>M</given-names></name>
<name><surname>Kaserer</surname><given-names>K</given-names></name>
<name><surname>Niederle</surname><given-names>B.</given-names></name>
</person-group> <article-title>Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment</article-title>. <source>Arch Surg</source>. <year>2001</year>;<volume>136</volume>:<fpage>49</fpage>-<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr14-1066896912457201">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khuroo</surname><given-names>MS</given-names></name>
<name><surname>Khuroo</surname><given-names>MS</given-names></name>
<name><surname>Khuroo</surname><given-names>NS.</given-names></name>
</person-group> <article-title>Treatment of type I gastric neuroendocrine tumors with somatostatin analogs</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2010</year>;<volume>25</volume>:<fpage>548</fpage>-<lpage>554</lpage>.</citation>
</ref>
<ref id="bibr15-1066896912457201">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grozinsky-Glasberg</surname><given-names>S</given-names></name>
<name><surname>Kaltsas</surname><given-names>G</given-names></name>
<name><surname>Gur</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours</article-title>. <source>Eur J Endocrinol</source>. <year>2008</year>;<volume>159</volume>: <fpage>475</fpage>-<lpage>482</lpage>.</citation>
</ref>
<ref id="bibr16-1066896912457201">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>RM</given-names></name>
<name><surname>Baybick</surname><given-names>JH</given-names></name>
<name><surname>Elsayed</surname><given-names>AM</given-names></name>
<name><surname>Sobin</surname><given-names>LH.</given-names></name>
</person-group> <article-title>Gastric carcinoids. an immunohistochemical and clinicopathologic study of 104 patients</article-title>. <source>Cancer</source>. <year>1994</year>;<volume>73</volume>:<fpage>2053</fpage>-<lpage>2058</lpage>.</citation>
</ref>
<ref id="bibr17-1066896912457201">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Solcia</surname><given-names>E</given-names></name>
<name><surname>Rindi</surname><given-names>G</given-names></name>
<name><surname>Paolotti</surname><given-names>D</given-names></name><etal/>
</person-group>. <article-title>Natural history, clinicopathologic classification and prognosis of gastric ECL cell tumors</article-title>. <source>Yale J Biol Med</source>. <year>1998</year>;<volume>71</volume>:<fpage>285</fpage>-<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr18-1066896912457201">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dakin</surname><given-names>GF</given-names></name>
<name><surname>Warner</surname><given-names>RR</given-names></name>
<name><surname>Pomp</surname><given-names>A</given-names></name>
<name><surname>Salky</surname><given-names>B</given-names></name>
<name><surname>Inabnet</surname><given-names>WB.</given-names></name>
</person-group> <article-title>Presentation, treatment, and outcome of type 1 gastric carcinoid tumors</article-title>. <source>J Surg Oncol</source>. <year>2006</year>;<volume>93</volume>:<fpage>368</fpage>-<lpage>372</lpage>.</citation>
</ref>
<ref id="bibr19-1066896912457201">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eckhauser</surname><given-names>FE</given-names></name>
<name><surname>Lloyd</surname><given-names>RV</given-names></name>
<name><surname>Thompson</surname><given-names>NW</given-names></name>
<name><surname>Raper</surname><given-names>SE</given-names></name>
<name><surname>Vinik</surname><given-names>AI.</given-names></name>
</person-group> <article-title>Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report</article-title>. <source>Surgery</source>. <year>1988</year>;<volume>104</volume>: <fpage>1046</fpage>-<lpage>1053</lpage>.</citation>
</ref>
<ref id="bibr20-1066896912457201">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Granberg</surname><given-names>D</given-names></name>
<name><surname>Wilander</surname><given-names>E</given-names></name>
<name><surname>Stridsberg</surname><given-names>M</given-names></name>
<name><surname>Granerus</surname><given-names>G</given-names></name>
<name><surname>Skogseid</surname><given-names>B</given-names></name>
<name><surname>Oberg</surname><given-names>K.</given-names></name>
</person-group> <article-title>Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids</article-title>. <source>Gut</source>. <year>1998</year>;<volume>43</volume>:<fpage>223</fpage>-<lpage>228</lpage>.</citation>
</ref>
<ref id="bibr21-1066896912457201">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Delle Fave</surname><given-names>G</given-names></name>
<name><surname>Kwekkeboom</surname><given-names>DJ</given-names></name>
<name><surname>Van Cutsem</surname><given-names>E</given-names></name>
<etal/>
</person-group>; <collab>Barcelona Consensus Conference participants</collab>. <article-title>ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms</article-title>. <source>Neuroendocrinology</source>. <year>2012</year>;<volume>95</volume>:<fpage>74</fpage>-<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr22-1066896912457201">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Safatle-Ribeiro</surname><given-names>AV</given-names></name>
<name><surname>Ribeiro</surname><given-names>U</given-names><suffix>Jr</suffix></name>
<name><surname>Corbett</surname><given-names>CE</given-names></name><etal/>
</person-group>. <article-title>Prognostic value of immunohistochemistry in gastric neuroendocrine (carcinoid) tumors</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>2007</year>;<volume>19</volume>:<fpage>21</fpage>-<lpage>28</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>